Cullinan Therapeutics Reports FY25 Results, Strong Cash Runway, and Key Pipeline Milestones

summarizeSummary

Cullinan Therapeutics reported its full-year 2025 financial results, showcasing a strong cash position with runway into 2029, alongside significant progress in its oncology and autoimmune pipelines, including a completed NDA submission and multiple upcoming clinical data readouts.

check_boxKey Events

• Strong Cash Position & Runway

  The company reported cash and investments of $439.0 million as of December 31, 2025, providing a projected cash runway into 2029 under its current operating plan, significantly de-risking near-term operations.

• Zipalertinib Regulatory & Clinical Milestones Achieved

  Cullinan's partner, Taiho, completed the rolling NDA submission for zipalertinib in 2L EGFR ex20ins NSCLC and fully enrolled the pivotal REZILIENT3 frontline study, with top-line results expected by year-end 2026. Cullinan is eligible for up to $130 million in regulatory approval milestones plus a 50/50 profit share in the U.S.

• Multiple CLN-978 Clinical Data Readouts Expected

  Initial clinical data for CLN-978 in Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) are confirmed for Q2 2026, with repeat dosing data in RA expected in Q3 2026, and initial data in Sjögren's disease (SjD) in Q4 2026.

• Increased R&D Investment Reflects Pipeline Advancement

  Research and development expenses increased to $187.4 million for the full year 2025, up from $142.9 million in 2024, contributing to a net loss of $219.9 million for 2025, reflecting significant investment in advancing its clinical pipeline.

auto_awesomeAnalysis

Cullinan Therapeutics' latest earnings report highlights a robust financial position with a cash runway extending into 2029, significantly de-risking its operations. The company also announced critical advancements in its pipeline, including the completion of a rolling NDA submission for zipalertinib and the full enrollment of a pivotal frontline study, with top-line results anticipated by year-end. Multiple clinical data readouts for its autoimmune program, CLN-978, are expected throughout 2026, providing significant catalysts for the stock. While the net loss increased due to higher R&D expenses, this reflects active investment in its promising clinical programs.